ImmuneOnco Biopharmaceuticals (Shanghai) reported FY 2025 results revealing a first-half revenue of C¥44.0 million and a basic EPS loss of C¥0.37, with ongoing net income losses totaling C¥152.6 million. The company has shown a trend of reducing losses by an average of 23.6% annually over five years, although it remains unprofitable with a trailing loss of C¥218.6 million on C¥154.3 million in revenue. The stock, currently priced at C¥4.46, trades at a P/S of 11x, which is higher than some peers but below the broader biotech sector average. Market sentiment remains mixed, highlighting both the positive long-term trend in loss reduction and concerns over current profitability and valuation.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1541/immuneonco-biopharmaceuticals-shanghai-shares/news/immuneonco-biopharmaceuticals-sehk1541-losses-narrow-236-ann
